Pediatric Lymphoma-Histiocytosis Fellowship

Program Description

The Texas Children’s Cancer and Hematology Centers Lymphoma/Histiocytosis Program at Baylor College of Medicine has organized a 12 month training fellowship to enhance the skills of board certified/eligible pediatric oncologists who want to gain special expertise in the care of lymphoma and histiocytosis patients. The lymphoma/histiocytosis center within the pediatric oncology section includes some of the nation’s most outstanding experts in the field of childhood lymphoma/histiocytic diseases. Over 140 new pediatric and adult histiocytosis patients are seen in our clinic every year including those with Langerhans cell histiocytosis, hemophagocytic lymphohistiocytosis, juvenile xanthogranuloma, Rosai Dorfman disease, and Erdheim Chester disease. More than 700 histiocytosis patients are followed by the center also. Among the 45+ new lymphoma patients seen each year are those with Hodgkin and non-Hodgkin lymphoma, post-transplant lymphoproliferative disease, peripheral T-cell lymphoma, and some less frequent forms. Several patients with autoimmune lymphoproliferative disease, Castleman’s disease, and rare lymphadenopathy syndromes are also followed. Once a month we have a joint immunology/lymphoma clinic to see patients with unusual lymphoproliferative disorders and immune deficiencies.

Goals and Objectives

To develop clinical expertise, leadership skills and research expertise in the field of lymphoma and histiocytic diseases

To provide advanced training in the evaluation, diagnosis, and management of children and adolescents with lymphoproliferative disorders, lymphoma and histiocytic diseases

To augment administrative and clinical expertise in the multidisciplinary field of pediatric lymphoma/histiocytic diseases

To improve the trainees’ knowledge of lymphoproliferative disorders, lymphoma and histiocytic disease biology in such a way that they will have a comprehensive understanding of this topic

To train individuals in the current Phase I, II and III therapies of pediatric lymphoma and histiocytic disorders such that they will have expertise in the clinical management of patients with this disease

To further enhance the teaching and leadership skills of trainees in this area

Program Eligibility

Candidates should be American Board of Pediatrics eligible for pediatric hematology-oncology or should have received equivalent training as judged by the program directors Only individuals who have successfully completed an ACGME-accredited fellowship in pediatric hematology-oncology or equivalent training are eligible for this advanced training opportunity

Program Duration

One Year

Program Dates

July 1st – June 30th, annually

Program Accreditation and Training Sites

  • Texas Medical Board: 503-48-05-34
  • Texas Children’s Hospital, University of Texas M.D. Anderson Cancer Center


The trainee will actively participate in several recurrent educational conferences:

  • Tumor Board: Tuesday afternoons (1 hr)
  • TXCH Departmental Research Seminar: Thursday mornings (1 hr)
  • Fellow’s Reflective Practice and Leadership Seminar: twice a month (1.5 hr/session)
  • Clinical and Research Mentor Meeting: weekly (1 hr)
  • Journal Review (selected topic regarding dendritic, T-cell or NK cell biology, lymphoma or histiocytic disease ): (1 hr)
  • Lymphoma/Histiocytosis Patient Radiology Review: weekly (1 hr)
  • Lymphoma/Histiocytosis Pathology Review: weekly (1 hr)
  • Histiocytosis Clinical Review: weekly (30 min)
  • Lymphoma Team Meeting: weekly (1 hr)
  • Laboratory Group Meeting: weekly (1 hr) Includes discussions of Genomics/Proteomics

Contact Us

1102 Bates Street, Ste. 1570
Houston, TX 77030
Program Director: Kenneth McClain, MD
Associate Director: Kala Kamdar, MD


Fellows interested in this fellowship training program must complete and submit an application along with two letters of reference, a curriculum vitae and a statement of interest. Learn more about how to apply for this fellowship.